MRNA vs WBD
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Oct 07, 2026
MRNA
WBD
Investment Advisor Scores
WBD
AI Analyst Insights
Detailed Metrics Comparison
| Metric | MRNA | WBD | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 23.0415 | 434.7826 | MRNA |
| PEG Ratio | 0 | 55.1758 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 2.1% | -11.2% | MRNA |
| Earnings Growth | -85.1% | -90.6% | MRNA |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 35.7/100 | 41.2/100 | WBD |
| Profit Margin | -141.4% | -8.8% | WBD |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | EXTENDED | HOLD | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
MRNA
MarkupPrice above SMA50, rising 50-day trend (49.6% over 20 days), RSI 64
WBD
MarkupPrice above SMA50, rising 50-day trend (4.5% over 20 days), RSI 75
Fundamentals Snapshot
| Metric | MRNA | WBD |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -41.0 | 4761.5 |
| Trailing P/E | — | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | -0.1% |
| Gross Margin | -0.7% | 0.5% |
| Operating Margin | -5.6% | 0.1% |
| EPS | -7.36 | -1.28 |
| Dividend Yield | — | — |